Novartis: Cost of capital and value creation: The spin-off of Sandoz
This case study explores the strategic spin-off of Sandoz, the generics and biosimilars division of Novartis, scheduled for October 2023. Set in late September 2023, the narrative follows financial analyst Stephanie Black of CVA Capital Ventures as she prepares cost of capital estimates for Novartis and its divisions. Her work aims to support a major portfolio rebalance at her investment firm and to assess whether the spin-off will create shareholder value.
Novartis, a Swiss-based global pharmaceutical leader, decided to spin off Sandoz to focus exclusively on high-value innovative medicines. Sandoz, on the other hand, would become an independent, publicly traded company, positioned as Europe’s largest generics pharmaceutical firm. The split is expected to improve strategic clarity and capital allocation for both entities.
The case provides detailed background on Novartis and Sandoz, including their business models, markets, revenues, and strategic priorities. Novartis’ innovative medicines division represents the bulk of its sales and is centered on research-driven patented treatments. Sandoz focuses on lower-margin, off-patent products, facing fierce competition but benefiting from growing global demand for affordable medications.
The central technical challenge in the case is estimating the Weighted Average Cost of Capital (WACC) for Novartis pre- and post-spin-off, and separately for Sandoz and the Innovative Medicines division. Stephanie must apply valuation techniques, particularly the Capital Asset Pricing Model (CAPM) for the cost of equity, and assess credit spreads and risk profiles for the cost of debt. Due to the lack of trading history for the separated entities, she also considers betas of comparable public companies.
The spin-off raises questions about potential value creation, changes in risk profiles, and operational trade-offs. While Sandoz gains agility and market focus, it also loses the financial stability and scale of Novartis. The case challenges students to assess whether the spin-off is likely to enhance shareholder value by reducing the cost of capital and sharpening strategic execution.
This case is ideal for advanced discussions on corporate finance, capital structure, valuation, and strategic management in the pharmaceutical industry. It provides rich data (financial statements, market conditions, credit spreads) and asks students to perform real-world estimations and strategic analysis.
What material is included in this case:
Description
This case study explores the strategic spin-off of Sandoz, the generics and biosimilars division of Novartis, scheduled for October 2023. Set in late September 2023, the narrative follows financial analyst Stephanie Black of CVA Capital Ventures as she prepares cost of capital estimates for Novartis and its divisions. Her work aims to support a major portfolio rebalance at her investment firm and to assess whether the spin-off will create shareholder value.
Novartis, a Swiss-based global pharmaceutical leader, decided to spin off Sandoz to focus exclusively on high-value innovative medicines. Sandoz, on the other hand, would become an independent, publicly traded company, positioned as Europe’s largest generics pharmaceutical firm. The split is expected to improve strategic clarity and capital allocation for both entities.
The case provides detailed background on Novartis and Sandoz, including their business models, markets, revenues, and strategic priorities. Novartis’ innovative medicines division represents the bulk of its sales and is centered on research-driven patented treatments. Sandoz focuses on lower-margin, off-patent products, facing fierce competition but benefiting from growing global demand for affordable medications.
The central technical challenge in the case is estimating the Weighted Average Cost of Capital (WACC) for Novartis pre- and post-spin-off, and separately for Sandoz and the Innovative Medicines division. Stephanie must apply valuation techniques, particularly the Capital Asset Pricing Model (CAPM) for the cost of equity, and assess credit spreads and risk profiles for the cost of debt. Due to the lack of trading history for the separated entities, she also considers betas of comparable public companies.
The spin-off raises questions about potential value creation, changes in risk profiles, and operational trade-offs. While Sandoz gains agility and market focus, it also loses the financial stability and scale of Novartis. The case challenges students to assess whether the spin-off is likely to enhance shareholder value by reducing the cost of capital and sharpening strategic execution.
This case is ideal for advanced discussions on corporate finance, capital structure, valuation, and strategic management in the pharmaceutical industry. It provides rich data (financial statements, market conditions, credit spreads) and asks students to perform real-world estimations and strategic analysis.
Learning Objective
This case is designed to help students understand how strategic corporate decisions—such as spin-offs—can influence a firm’s cost of capital, valuation, and long-term value creation. It is particularly well-suited for MBA or executive programs in finance, strategy, or healthcare management, and can also be effectively used in more advanced electives on corporate finance or valuation.
The class discussion should begin by focusing on the estimation of the Weighted Average Cost of Capital (WACC). Students will explore the components of WACC, including the cost of equity—calculated using the Capital Asset Pricing Model (CAPM)—and the cost of debt. The case allows for a rich discussion of how business risk, capital structure, and credit ratings impact these components. Since the spin-off entities do not have separate trading histories, the case also provides an opportunity to work with peer comparables to estimate divisional betas, which is an essential technique in real-world valuation.
Another major focus of the session should be the valuation implications of the Sandoz spin-off. Students will evaluate how splitting Novartis into two distinct entities with different risk and growth profiles may affect investor perception and overall company valuation. This opens the door to discussions on whether and how spin-offs can unlock shareholder value by improving strategic focus, optimizing capital allocation, and aligning investor expectations more clearly with each business.
Strategically, the case offers the opportunity to explore the motivations behind corporate restructurings. By separating its generics division, Novartis aims to become a pure-play innovative medicines company. Students can debate the potential benefits—such as increased managerial accountability and organizational agility—against the risks, including the loss of scale-related synergies and a potentially higher cost of capital for the standalone entities.
The narrative setup, which follows a financial analyst at an investment firm, positions students in a realistic decision-making context. They are asked to take the perspective of an investor assessing the implications of the spin-off, making the case ideal for engaging participants in both quantitative valuation exercises and strategic reasoning. This dual focus makes the case a strong fit for integrated learning objectives across finance and strategy, especially in MBA or executive education programs that aim to connect analytical tools with high-level business decisions.
Leave your rating
"Novartis: Cost of capital and value creation: The spin-off of Sandoz"
Register for free with IESE Publishing and enjoy all the advantages
What type of account do you want to create?
Choose account type
Professors
Academic Institutions
Companies
Individuals